News Archive

Press Release Archive

• Mitsubishi Tanabe Pharma Canada, inc. To Discontinue RADICAVA^® IV (edaravone)

  TORONTO, ON, October 4, 2024 –...

  Read More
  October 4, 2024
• Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Now Eligible For Coverage Through Veteran Affairs Canada And Indigenous Services Canada

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  December 13, 2023
• Mitsubishi Tanabe Pharma Canada Celebrates Five Years in Canada Supporting And Committed To People Living With ALS

  Mitsubishi Tanabe Pharma Canada Celebrates...

  Read More
  November 29, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plans In Prince Edward Island, Newfoundland And Labrador

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  November 7, 2023
• Canadian-Developed AI Technology Aims To Support Early Detection Of ALS

  Canadian-Developed AI Technology Aims To...

  Read More
  September 20, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plans In Saskatchewan

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  September 1, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plans In New Brunswick And Nova Scotia

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 29, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In British Columbia

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 18, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Québec

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 16, 2023
• Mitsubishi Tanabe Pharma Canada Announces Collaboration With The CNDR On First Canadian Real-World Evidence Study Of RADICAVA® IV (edaravone) Survival Benefits In ALS

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 9, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Alberta

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 3, 2023
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Ontario

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 1, 2023
• Mitsubishi Tanabe Pharma Canada Concludes Letter Of Intent With Pan-Canadian Pharmaceutical Alliance For prRADICAVA® Oral Suspension (edaravone)

  Mitsubishi Tanabe Pharma Canada Concludes...

  Read More
  July 20, 2023
• Mitsubishi Tanabe Pharma Canada Is Proud To Support A New HCP Directed Program: How To Break The News In ALS/MND

  Mitsubishi Tanabe Pharma Canada Is Proud...

  Read More
  June 14, 2023
• Mitsubishi Tanabe Pharma Canada Announces New Leadership

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  April 3, 2023
• Mitsubishi Tanabe Pharma Canada Receives Engagement Letter From Pan-Canadian Pharmaceutical Alliance For ᵖʳRADICAVA® Oral Suspension

  Mitsubishi Tanabe Pharma Canada Receives...

  Read More
  March 30, 2023
• Mitsubishi Tanabe Pharma Canada Announces ᵖʳRADICAVA® (Edaravone) Oral Suspension Is Now Available In Canada For The Treatment Of Patients With ALS

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  February 10, 2023
• ᵖʳRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation From INESSS For The Treatment Of Patients With ALS

  ᵖʳRADICAVA® (Edaravone) Oral...

  Read More
  January 18, 2023
• ᵖʳRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation From INESSS For The Treatment Of Patients With ALS

  ᵖʳRADICAVA® (Edaravone) Oral...

  Read More
  December 19, 2022
• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization Of ᵖʳRADICAVA® (Edaravone) Oral Suspension For The Treatment Of Patients With ALS

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  November 8, 2022
• Mitsubishi Tanabe Pharma Canada Announces Publication Of Real-World Data For Radicava® (edaravone)

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 15, 2022
• Health Canada Accepts SNDS Filing And Grants Priority Review For Oral Edaravone Formulation For The Treatment Of ALS

  Health Canada Accepts SNDS Filing And...

  Read More
  May 13, 2022
• Mitsubishi Tanabe Pharma Canada Announces That Prince Edward Island Has Added The Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) To Its Provincial Drug Formulary

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  November 23, 2021
• Mitsubishi Tanabe Pharma Canada Announces That Treatment For Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland And Labrador Prescription Drug Program

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  March 10, 2021
• MTP-CA Applauds The Release Of Canada’s First ALS Management Guidelines

  MTP-CA Applauds The Release Of Canada’s...

  Read More
  November 18, 2020
• Mitsubishi Tanabe Pharma Canada Announces Treatment For Amyotrophic Lateral Sclerosis (ALS) Now Eligible For Coverage Through Veterans Affairs Canada And Indigenous Services Canada

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  September 21, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To British Columbia PharmaCare Formulary

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  August 19, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia Has Added The Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) To Its Provincial Drug Plan Formulary

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  July 7, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Manitoba Has Added The Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) To Its Provincial Drug Plan Formulary

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  June 30, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  June 30, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan In New Brunswick

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  June 18, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Alberta

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  June 1, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Ontario

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  May 28, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added To The Provincial Drug Plan In Quebec

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  April 29, 2020
• Mitsubishi Tanabe Pharma Canada Concludes Letter Of Intent With Pan-Canadian Pharmaceutical Alliance For RADICAVA® (edaravone)

  Mitsubishi Tanabe Pharma Canada Concludes...

  Read More
  April 22, 2020
• MTP-CA’s Response To COVID-19

  MTP-CA’s Response To COVID-19 March 20,...

  Read More
  March 20, 2020
• Mitsubishi Tanabe Pharma Canada Announces Availability Of RADICAVA® (edaravone) For Amyotrophic Lateral Sclerosis

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  November 5, 2019
• Update On Canadian Product Availability

  Update On Canadian Product Availability...

  Read More
  October 22, 2019
• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization Of RADICAVA™ (Edaravone) To Treat ALS

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  October 4, 2018
• New Country Manager Brings Significant Business Leadership And Healthcare Expertise To Mitsubishi Tanabe Pharma Canada, Inc.

  New Country Manager Brings Significant...

  Read More
  September 28, 2018

Load More